ASCO/CAP clarifications to ER/PR/HER2 testing guidelines

April 20, 2011

ASCO/CAP clarifications to ER/PR/HER2 testing guidelines

ASCO is publishing a clinical notice regarding clarifications to previously published guidelines for HER2 testing and estrogen receptor (ER) and progesterone receptor (PR) testing in breast cancer. A summary can be found at the CAP Web site.

The clarifications were needed since these tests are generally run on the same specimen in routine practice and reconcile discrepancies between the two guidelines regarding cold ischemia time, handling of remotely obtained specimens, appropriate fixation times in NBF, and selection of optimal areas for testing.

This is a welcomed development for us practicing grunts (who must acknowledge, explain and document this stuff) but shouldn't affect current routine practice or patient testing.

Apr 20, 2011 2:43:39 PM | Breast cancer, College of American Pathologists, Prognostic/Predictive Cancer Markers

The comments to this entry are closed.

Hallmarks of cancer v. 2.0 In 2000, Douglas Hanahan and Robert Weinberg initially proposed six hallmarks of cancer that form an organizing principle for understanding the remarkable diversity of "cancer." Their update, "Hallmarks of Cancer: The Next Generation," was published in the March 4, 2011...

Notes and impressions from CAP Futurescape '11 First, a disclaimer. I was only able to attend CAP Futurescape on Saturday, April 16. Although this was the majority of the conference, the Sunday morning session had a great lineup of speakers talking personalized/genomic medicine. I tried my thumbs...